ADH-503;ADH503;ADH 503
|
|
|
- CAS号:
- 2055362-74-6
- 英文名:
- ADH-503
- 英文别名:
- ADH503;ADH 503;ADH-503;ADH-503;ADH503;ADH 503;ADH-503 [(Z)-Leukadherin-1 choline;ADH-503 - Leukadherin-1 choline salt;2-Hydroxy-N,N,N-trimethylethan-1-aminium (Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoate;tumor-infiltrating,CD11b,ADH-503,Inhibitor,tumorassociated,dendritic,immunosuppressive,macrophages,repolarization,allosteric,inhibit,Complement System,ADH503,orally,ADH 503
- 中文名:
- ADH-503;ADH503;ADH 503
- 中文别名:
- 化合物ADH-503;ADH-503(鎓盐);LEUKADHERIN-1 CHOLINE SALT;(Z)-4-[5-(3-苄基-2,4-二氧代噻唑烷-5-亚甲基)-呋喃-2-基]-苯甲酸 (2-羟基-乙基)-三甲基铵盐;2-羟基-N,N,N-三甲基乙烷-1-氨基鎓(Z)-4-(5-((3-苄基-4-氧代-2-硫代噻唑烷-5-亚基)甲基)呋喃-2-基)苯甲酸盐
- CBNumber:
- CB35582357
- 分子式:
- C27H29N2O5S2+
- 分子量:
- 525.66
- MOL File:
- 2055362-74-6.mol
|
|
|
ADH-503;ADH503;ADH 503化学性质
-
储存条件:
-
Store at -20°C
-
|
-
溶解度:
-
DMSO: 21.43 mg/mL (40.85 mM)
-
|
ADH-503;ADH503;ADH 503性质、用途与生产工艺
ADH-503 ((Z)-Leukadherin-1 choline) 是一种具有口服活性的，变构的 CD11b 激动剂。ADH-503 可以导致与肿瘤相关的巨噬细胞重新极化，减少肿瘤浸润性免疫抑制骨髓细胞的数量，并增强树突状细胞的反应。
ADH-503 ((Z)-Leukadherin-1 choline; 4 μM; 8 days) reduces the numbers of total tumor-infiltrating CD11b
+
cells and subsets of CD11b
+
monocytes, granulocytes, eosinophils, and macrophages.
ADH-503 ((Z)-Leukadherin-1 choline; oral gavage; 30, 60, or 120 mg/kg; twice a day for 60 days) delayes tumor progression, leading to a significantly decreased tumor burden in time-point analysis and improved overall survival.
ADH-503 (oral gavage; 30, 100 mg/kg; twice a day; on days 1 and 5) has the mean half-life of 4.68 and 3.95 hours, a maximum concentration of 1716 and 2594 ng/mL and AUC
0-t
in the plasma of 6950 and 13962 ng.h/mL at 30 and 100 mg/kg dosing, respectively.
|
Animal Model:
|
KPC mice [p48-CRE/Lox-stop-Lox(LSL)-Kras
G12D
/p53
flox/flox
]
|
|
Dosage:
|
30, 60, or 120 mg/kg
|
|
Administration:
|
Oral gavage; 60 days
|
|
Result:
|
Delayed tumor progression, leading to a significantly decreased tumor burden in time-point analysis and improved overall survival.
|
|
Animal Model:
|
Male rats
|
|
Dosage:
|
30, 100 mg/kg (Pharmacokinetic Analysis)
|
|
Administration:
|
Oral gavage twice a day; on days 1 and 5
|
|
Result:
|
Had the mean half-life of 4.68 and 3.95 hours, a maximum concentration of 1716 and 2594 ng/mL and AUC
0-t
in the plasma of 6950 and 13962 ng.h/mL at 30 and 100 mg/kg dosing, respectively.
|
ADH-503;ADH503;ADH 503
上下游产品信息
上游原料
下游产品
| 更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
|---|
| 2024/04/30 | HY-15701B | ADH-503;ADH503;ADH 503
ADH-503 | 2055362-74-6 | 5mg | 550元 |
| 2024/04/30 | S0525 | ADH-503;ADH503;ADH 503
ADH-503 | 2055362-74-6 | 5mg | 876.68元 |
ADH-503;ADH503;ADH 503
生产厂家
2055362-74-6, ADH-503;ADH503;ADH 503 相关搜索:
- 药靶配体
- 制剂-激动剂
- 2-羟基-N,N,N-三甲基乙烷-1-氨基鎓(Z)-4-(5-((3-苄基-4-氧代-2-硫代噻唑烷-5-亚基)甲基)呋喃-2-基)苯甲酸盐
- ADH-503(鎓盐)
- 化合物ADH-503
- LEUKADHERIN-1 CHOLINE SALT
- (Z)-4-[5-(3-苄基-2,4-二氧代噻唑烷-5-亚甲基)-呋喃-2-基]-苯甲酸 (2-羟基-乙基)-三甲基铵盐
- 2055362-74-6
- tumor-infiltrating,CD11b,ADH-503,Inhibitor,tumorassociated,dendritic,immunosuppressive,macrophages,repolarization,allosteric,inhibit,Complement System,ADH503,orally,ADH 503
- 2-Hydroxy-N,N,N-trimethylethan-1-aminium (Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoate
- ADH-503 [(Z)-Leukadherin-1 choline
- ADH-503 - Leukadherin-1 choline salt
- ADH-503;ADH503;ADH 503
- ADH-503
- ADH503
- ADH 503